Thyroid Hormone Action

$214,429R01FY2006DKNIH

Oregon Health & Science University, Portland OR

Investigators

Linked publications & trials

Paper 34375614 Paper 33422763 Paper 32169163 Paper 30996143 Paper 30770568 Paper 30655956 Paper 30654068 Paper 29892826 Paper 29846550 Paper 29845892 Paper 29625991 Paper 29200204 Paper 28943663 Paper 28756656 Paper 28428265 Paper 28385597 Paper 28316349 Paper 28200172 Paper 27707627 Paper 23702093 Paper 23512955 Paper 22948220 Paper 22885046 Paper 22128163 Paper 22036195 Paper 21664427 Paper 21239431 Paper 20623079 Paper 20358049 Paper 20155805 Paper 19729063 Paper 19280098 Paper 19256523 Paper 19116337 Paper 19105176 Paper 19074582 Paper 18930112 Paper 18823891 Paper 18821722 Paper 18752950 Paper 18558711 Paper 18420141 Paper 18339710 Paper 17988877 Paper 17690312 Paper 17530732 Paper 17497842 Paper 17284482 Paper 17204552 Paper 17168554 Paper 16451074 Paper 16116342 Paper 16081636 Paper 16040072 Paper 15796525 Paper 15235810 Paper 15146179 Paper 15100213 Paper 14701670 Paper 14683517 Paper 12825953 Paper 12825456 Paper 12109914 Paper 12095994 Paper 11891331 Paper 11741782 Paper 11597408 Paper 11435461 Paper 11150243 Paper 11128634 Paper 10965874

Abstract

DESCRIPTION (provided by applicant): The long-term objective of this project is to understand the molecular mechanisms of thyroid hormone action. Thyroid hormone is an important regulator of development and homeostasis, and abnormalities in thyroid status correlate with many human diseases ranging from cancer to birth defects to metabolic disorders. Thyroxine (T4) is the major form of thyroid hormone that is secreted from the thyroid gland, and T4 is metabolized to the active hormone T3 by enzymatic deiodination. T3 regulates the transcription of thyroid hormone responsive genes by binding to and activating nuclear thyroid hormone receptors. However, there are many effects of thyroid hormone that occur much faster than the timescale of transcriptional regulation, and the molecular mechanisms of these rapid effects are unknown. This research plan is constructed around the hypothesis that rapid thyroid hormone signaling involves a novel metabolite of T4 that is chemically distinct from T3. This hypothesis is supported by experiments showing the existence of this novel metabolite in tissue, as well as the induction of rapid physiological responses when the metabolite is administered in vivo. In addition, this T4 metabolite is a potent agonist of a newly discovered orphan G protein-coupled receptor (GPCR) related to the family of a biogenic amine GPCRs. This research plan seeks to further explore this novel pathway of thyroid hormone signaling. Specific aim 1 involves chemical modification of the metabolite to delineate the structural features important to GPCR activation. Specific aim 2 is a study to understand the enzymology responsible for generating the rapid-acting T4 metabolite. Specific aim 3 involves the isolation, expression, and pharmacological characterization of the different subtypes of the GPCR that responds to the metabolite. Specific aim 4 is an approach to examine different tissues for the presence of the metabolite and perform quantitative analysis. Specific aim 5 is a plan to develop a chemical antagonist of the metabolite that will be useful for studying the in vivo biology of this new thyroid hormone signaling pathway.

View original record on NIH RePORTER →